ATNX - Earnings call transcript Q3 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen, and welcome to the Third Quarter 2020 Athenex Earnings Conference Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to hand the conference over to Mr. Athenex. of Rubis Steve ahead. go please Sir,

Steve Rubis

results the Good detailing morning Company's morning Today, archived the the wire business our A call. on also be results for well XXXX. thank will provide you replay for financial of the The and we the of earlier Athenex's a joining quarter an available website. of is news crossed as release will conference Company review on website. this and this third call update as on

call, may and the filings or milestones, you or which Company's and During business statements results will forward-looking XXXX the statements the from encourage the clinical conference events to Company past review about differ make regarding to described statements. future anticipated and the including forward-looking cause in materially year the We projections in actual fiscal future factors with events, that those SEC, beyond. identify specific financial,

Dr. Medical Randoll Chief Cook, over to Officer; Officer; comments. Kwan, Operating You the EDGAR can www.athenex.com. we find introductory our Dr. Sze, I www.sec.gov Timothy are Rudolf Global Senior and Yordon, website turn Executive Mr. Mr. Commercial President, the call Mr. Chief joined Relations Financial Johnson This Vice Jeff at Investor Oncology. or at morning, Officer; Officer; by the our at database Chief now section Lau, SEC filings Chief in will Johnson in for

Dr. Johnson Lau

Oral action the a priority a of time. In high-level Oral Dr. our closer of two same February The the and in under the goal FDA excellent strong to I'll a clinical with becoming year of call leading Thank acceptance quarter are turning is under a discuss date our review target NDA puts of now accepted company. progress made to commercial position our September, Kwan provide we you, before the stage to programs. Rudolf that Athenex at for FDA this progress opportunities NDAs review Paclitaxel Steve. overview the having the The the made oncology Athenex Paclitaxel future during for at XX, review FDA of XXXX. over

Within We oral all medical the around both for communities chemotherapy, demand options. value COVID-XX, therapy context and oral continue experiencing currently, for of highlights greater the of formulations. convenience patient

As discussed from switching NCCN when an an therapies is formulation calls, previous on available. recent guidelines patients encourage oral infusion-based equipment to

FDA current appears the the can keep of pandemic on Additionally, supportive that therapy therapies help environment. patients in

where successful elements our our our completely Market of is for place cancer for additional Paclitaxel These initially breast pathways XX,XXX negative. be of Paclitaxel and additional triple These will addition a Timothy chemical launch. on is negative care are cancer details Mr. Cook mostly hormone in on patients are Jeff include and Yordon breast addressable opportunities market. patients in metastatic settings assets, settings roughly Oral that Certain shows research team opportunity represent commercial Oral now the the all commercial in expansion trials, initiatives. build-up focused the The cancer provide Oral market In the who positive, annually Paclitaxel key who total significant. to to combination expand putting and exist further other U.S. indications. will HERX prescribed infrastructure or represent standard Mr.

over X.X than the breast can is If expand cancer. time example, early-stage more to million total For patients. Oral in market X in the TRIAL addressable I-SPY Paclitaxel areas, successful evaluating these

Athenex September, closely is IND of application U.S. with and XX the XXXX. as and place preparation. markets, reached for another allow Tirbanibulin for the represent having IND agency TCR-T NY-ESO-X European work accepted for of continue and December the working geographic partner with a The We our solid FDA the are China, we Almirall first by strategy regulatory the on XX, ointment milestone areas. U.S. date FDA our tumors. Europe tirbanibulin the important high-value get TCRT-ESO-AX, in ointment In tirbanibulin cell other review. them product positive to its for also to targeting partners review to our undergo launch therapy, is in PDUFA

fact, being joint and sales perform developed Therapeutics, business In TCRT-ESO-AX and third up Athenex in by venture revenue a quarter, expectations. Xiangxue the commercial continues million Limited. The to year-over-year. Product $XX.X Axis Life Sciences XX% totaled is well between existing beat

guidance our mid-teen raising low sales to As percentage full year a result, growth. XXs from we are product

quarter, million. us announced This clinical to I balance over strengthened call launch million. net planned with Oral the additional Paclitaxel Medical our the proceeds commercial allow to for funds us will our Officer, provide in financing the to by funded and further and the Rudolf? pipeline. recently turn Oaktree undertake of Dr. raising with strengthen to Partners, label commercial of $XXX Sagard we of also which now resources Oral our infrastructure. expansion During financings develop our provide The further total with Rudolf one of equity overview will $XXX They September programs. initiatives sheet and be provide Paclitaxel a expand nondilutive a successful combined Royalty Kwan, Chief we an Healthcare will

Dr. Rudolf Kwan

Good everyone. morning,

Oral During important were the Paclitaxel. quarter, regarding there two developments

we with NDA a the encouraging of the for Paclitaxel target dialogue assigned by is pleased FDA date. our XX, date and XXXX. February Ongoing PDUFA the Oral progress are to and FDA with First, action accepted was

Oral trial in and a TRIAL. the GSK's also chance there setting. X become drug, dosing with drug efficacious provides combination study the an to of inclusion objective combination Second, good to cure design a is The which choice are the a it with drug. Paclitaxel's I-SPY Sites the breast X has patients in I-SPY for work opportunity The study Paclitaxel already of to The this dostarlimab The Oral I-SPY study the lead combination actively the cancer the arms targeting IV Paclitaxel inclusion shown benefit TRIAL is of backbone for in an in Paclitaxel anti-PD-X. Oral combination us cancer. in to with anti-PD-X as demonstrate breast X be for pembrolizumab, believe as opportunity Company with treatment is announced presents early-stage for approaches. to vaccine been

Leap went several several on other readout have to X have in Oral trial evaluated within a data Paclitaxel GSK. Athenex is years been and around months, credibility time I-SPY program. context receive Quantum the arms of our The suggests of I-SPY in to inclusion after broader the excited important timing, arena, trial possibility of readout approval. collaborate trials XX the X roughly for this I-SPY trial eventually clinical frame. which the in of oncology I-SPY agents Regarding an clinical elevates the and Quantum Leap's represents with

Paclitaxel Breast angiosarcoma Paclitaxel the breast on actual We focus Paclitaxel XX. the are primary updated poster subset presentation from on There will of our pivotal PFS pending a will metastatic who update presented posters is side Phase Cancer presentation develop trial the for Oral Symposium have A the Currently, and tirbanibulin will in December for our time. from discussion. for embargoed X GI the until also to be present of OS San Virtual presentation at poster the management ointment. Oral approval abstracts trial Oral four angiosarcoma Antonio effects. Company taking OS be on data These and III include and of a patients further cancer, breast. place abstracts of the The in PFS update neuropathy accepted poster and which spotlight

management therapies strategy important Our and our focus life is expansion studies, cycle Paclitaxel new for indications. combination Oral next around label

and on updates approval. track over product will about to provide review to Tim turn is I the XX, Almirall from date. PDUFA months. upon FDA the to our be additional a by we goal and coming the U.S. the for E.U. expect FDA The commercializing Cook Our December ointment commercial the pipeline tirbanibulin receive remains call the response the now in update. will the in of

Timothy Cook

The stages XX, Rudolf. The commercial date February or of the planning FDA final for are Company you, action to immediately of underway. XXXX Oral prepared Paclitaxel upon launch is earlier. Thank

our recap me Let progress.

leaders. discussions with key in opinion engaging Our science place is and liaison team in medical is scientific

Our meantime, patient and and team begin information the around disease side discussions profiling are dosing managing having the start territories teams local oncology its on on treatment care. will board the state and nurse effects to unbranded will upon the In oncology educators provide and launch.

Kaiser. of the regional hired have Activities facilitate large about two customers directors quarter. Paclitaxel Based budget order in Act the may these We economic during allocations. target the at national on focused and third account in is account to directors drug on or Preapproval approval. coverage hiring decisions with Information networks Exchange to community to payers policy the Oral ahead health integrated delivery five a to like account corporate payers of educating payer smaller pertaining Athenex engage managers national information and process cover care level establishing the PIE,

and the positive our as is value of with initiatives frame are key time Our finalized. and our distribution prior last pricing on Feedback finalizing step in Developing pricing ahead focus. up and parallel, specialty a Contracts view drug has in Oral In involves the onboarding contracting our our representatives and in December-January to expected strategy. work Paclitaxel of are payer proposition community our we wrapping the launch. place assumptions. outreach innovative, distributors is which payers been overwhelmingly all line remain model our key as with pharmacies, patient our sales

Beth very amplifying pharmacy additional cancer point used tour month. to the to of breast facing and virtual month. of near media financial cancer across is is multiple system development. manage has a hub and in focused final radio force cancer which as awareness both October accompanied its are by program to voice visibility Athenex support share stages social around our featuring breast specialty help and assisted reimbursement a held been to platforms. guide October consisted of messages patient X on Core Company well An be contact Our marketing interviews in patients. launched The on through breast and sales treatment the TV post the for Dr. media completion. and a provide as was metastatic active created by of DuPree,

taxane shows pre-medicate need a efficacy positively reactions. Our of first our that are the to around the oral language neuropathy, infusion market Physicians research to safety no lack well. responding messages and resonate around and patients

presence Symposium. a Antonio San We Breast the Cancer will at have

exhibit. the to we that Rudolph also virtual will abstracts addition have In mentioned, a four

out we roll initiatives ready Oral are prepared staff Lastly, will upon after has targeting begun for launch and that launch. we Paclitaxel finalized patients. brand to physicians, we summarize, outreach approval. To office Payer Oral the have Paclitaxel campaign and

several be upon drug. planning the can are physician that promote we outreach approval Additionally, to events virtual rapidly deployed

call the Jeff Yordon, to I'll Now our over turn COO.

Jeff Yordon

you, Thank Tim.

we and these all elements Athenex having Our have company in also and once on Doing strategy clinical, first a running marketing, well launch. capture for manufacturing the integrated can of sales functions focuses regulatory, supply and across so place vertically a approval. building we planned the commercial the value at ahead It our entire ability to the hit provides ground chain. means are

Polymed's as XXXX. The XX new will as XX of half nearly and order, I current on facility facility source financials. APS markets of essential and quality the A products for commercial In our The and which which of than in over our months. well. portion China-based can products products expectation square well needs this XXXB for Dunkirk, launch. facility feet the business is finished. specialty to begin second to planned product in API XXX,XXX now Europe terms place a is production, facility dedicate facility production plan for and our those currently is six ready pharmaceutical XX well a will products large be products should more clinical to in the manufacturer XX is supply manufacturing manufacture interior in second markets our operational call York work Chongqing SKUs, complete later remains as as turn eventually to is commercial APD of facility to XX as year and trials. as in Construction launch Randoll proprietary is almost be for our that all delivered is of will The New equipment in well. to exterior API with and as the injectable as serve Dunkirk The discuss and high supply leading with the SKUs.

Randoll Sze

by the increase increased health an million, to you, offset year million primarily product million product totaled continued suspended by Jeff. driven million sales facility from recognized an production drugs. license present led The Within global sales pharmaceutical $XX.X as from XXXX specialty ago, we and the as PharmaEssentia, was of batches pandemic $X.X the quarter demand in for API related forecast. of Cost The $X.X VAT XX%. sale. compared product respectively. Revenues agreement impact of totaled of in quarter pursuant revenue partially growth. ago. and specialty revenue the to third $XX.X COVID-XX sales at $X business third increased our API Thank a $XX.X which specialty license Xiangxue line in revenue, million revenue again million a of agreement license product this growth for beat for compared In to of a decline increase this the to was once $XX.X our $XX.X in net sales, with of commercial million sales sales and quarter, we XXXB million year and with product out-licensing rate totaled Cost the

our was compared cost $XX.X $XX.X were fixed to decreased Hanmi in well partially XXXX period license costs in increase in for expenses senior and a ago. Operating expenses million Xiangxue sales, year expenses proceeding similar at incur million drug totaled of associated agreement. the compared year license medical of in million production devaluing and decreases and despite costs, sublicense result totaled offset to Oaktree's in in relation Of with costs, $X operations loan in assignment a note to $X.X the EBIT costs quarter down secured we million by did co-investors Commercial expenses the below to recognized a revenue was a the $XX.X to expenses ago. decline recognized licensing million as ago. payable winding fees incur million We the R&D from the to the comp. same $XX.X year. The facilities. API compared drug nature pre-clinical our drove API $XX.X $XX.X III compensation We Sagard. million expenses. million was increase an attributable to SG&A approximately continue related $XX.X studies as loss portion R&D loss Decline line, the costs. the APS million preparation all year of of Out with of the a a is gears to last not regulatory Phase R&D of to and proprietary

loss per to QX $X.XX Athenex with result $X.XX foregoing, $XX.X a of XXXX attributable the in As million share net per or $XX.X compared XXXX. was diluted million QX or in share

net to per QX loss extinguishment $XX.X Athenex of $X debt million expenses was onetime million, the Excluding the $X.XX share. in attributable diluted XXXX or

are In our rate percentage performance our the at into raising expect mid-teen our full remainder outlook of well takes This product again year-to-date terms with in of We we XX guidance year account for of the August. we guidance, growth the sales now XXXX. growth this as the a that communicated low as the sales year-over-year for year. least

products revenues COVID mix, we to that treat product nature. do view improve continue Our we these are not to recurring patients in used though as

includes only milestone our or product partnership reminder, sales. guidance provide a don't revenues As guidance payments. on We

stock and remarks. per share. In cash XX-day restricted Athenex of and option short-term common cash $XXX.X a at of an September, equivalents investments Oaktree the milestones to X.X debt million. turn investments be for to $XX.X which the purchase through million our we granted Company expense, public XXXX, I million signed of operating will associated operations an activities of we was from of XX, to of Sagard XXXX. current exercised call XXXX, expect non-dilutive and now full. shares, offering shares up Based Johnson priced and September cash XX, available equivalents, fund our with in million with on underwritten cash The and $XX XX into had as closing Net operating $XX.X proceeds million. and were additional over Capital our restricted made the cash of cash will agreement the generated short-term cash underwriters million, completed As the with together $XXX.X September capital to

Dr. Johnson Lau

company, stage a across to the thank business execution Thank delighted I products. their to of from proprietary for focusing and development work I'm registration their want you, for two hard the colleagues the Company and throughout successful my on planned commercial year. to evolving Randoll. the launch see

will now call questions. for the We open

Operator

the Karnauskas first comes line Our Robyn Truist from Instructions] [Operator Securities. with of question

Robyn Karnauskas

regarding So inhibitor Oral checkpoint Pac I just combo. had a and question

So just X, for clarify. I-SPY to I want

about XX through And that that for your potentially how or Pac should just about oral track talked XXXX? trial. on your a to I-SPY coming and think year-end from the are go think walk then could drug out the you still we're that picture for what months, year? from would we 'XX maybe Oral You trial into be X us you time for a trial the it lines the Mayo opportunity trial, follow-up or bigger Can and data next reads -- tirbanibulin

Dr. Johnson Lau

Rudolf?

Dr. Rudolf Kwan

I-SPY are of Robyn, X studies conducting. we combination the is one the

it combination in we in project setting, based based cannot along keep the GSK has was enrollment. in really started a very cancer. we So setting neoadjuvant The The be and moving well. dostarlimab with that on timing. as breast enrollment metastatic on will it's saying, the is But readout,

at occurs looking the from around months XX previous start. readout the I-SPY programs, January time after Just they lines

timing life inhibitor as pembrolizumab And about cycle is right. talking your it do underway. So lot depend we enrollment projection. more a have will a time using that The answer our know combination progressing immunotherapy the we anti-PD-X guidance, to question. plans as do that's is progress. area. or management and that really have we rate. include the with as have And Everything be been other checkpoint actual hope study I We when will well we on line important we programs O-XX the not already in will an

Operator

with comes next question Capital Kennen Markets. from of Our the MacKay RBC line

Kennen MacKay

despite year very the COVID-XX of execution pandemic. a impressive so far on Congrats

another I that I checkpoints combination to. speak Rudy question on of the with First, and one Oraxol was could question manufacturing and on quick hoping Johnson had then

to and you So there. there, manufacturing been than inspected us tirbanibulin wondering the first, checkpoint FDA each And the yet for was see the busy been for whether is has I by Oraxol these the as very plan more manufacture obviously manufacturing pushed plants where of could question the in Maybe that FDA Maybe on some a and to paclitaxel But second we've checkpoints to hoping differences product. a you had in checkpoint this then -- the days. so supply inform the of plants trial, Abraxane plus Oraxol, drug effects bit and to referring there. far cancer. initially combo. I'm see or need whether breast the paclitaxel if obviously commercial you could you specifically plus biggest the that for we're of data impact there IV talk seeing of on of between the the seen checkpoint, differences and versus around obviously some little being and with steroid pretreatment a and XXX immunologic so XXX the some some

Dr. Johnson Lau

For want the do first you a to Jeff, comment? question make on manufacturing,

Jeff Yordon

Yes.

is First inspected a a Kennen, developed on has of being all, basis. the regular been partner Oral Paclitaxel by who

is with facility that ready Clarence, make Where very very, the we have we inspections tirbanibulin had in several to So ointment go. good results.

So will to with quick ready slow the go. issue that down inspections anything. is not there's no answer FDA We're

Dr. Johnson Lau

manufacturing facility, Kennen, FDA at all. tirbanibulin that the know little communicate to no issue Just the for did own a bit for ointment three add before you we more, inspection in Basically, citations. our the

also IO therapy the paclitaxel, address XXXXX second particular your in you Rudolf vaccine a and to to combo the regard question? on between with with study this IV and do the want Now question also contrast

Dr. Rudolf Kwan

observation. It's interesting Absolutely.

difference. suggest the probably presumably use on think understand steroid But dose. study addressed use difference Abraxane one be before the clearly will each between not to IV you lot arm did steroid before the and can the paclitaxel surface, definitively as of the the two I have a questions

-- Oral So Paclitaxel interesting. that is difference. The is very one our combination

question dosing first about not all, PK has okay? kind steroid, do with because from of different a our And lot been being of for be is in that along So talk setting, will in we need And no regimen combination profile it a like of immunotherapy. regimen certainly, dosing best in not it's the interesting yet. there's addressed And the HERX oral, whether antihistamine. way, it the the what combination vaccine,

obviously, very our and in So would with efficacy there to is profile, into. interesting neuropathy be PK look showing benefits

better see inhibitor. await of our eagerly versus our we even So combination paclitaxel arena data study can we from of in checkpoint whether to with the differentiate the

hope question. Kennen, answered I So, your I

Dr. Johnson Lau

is bit is that steroid, remember Kennen, color I very and of coordination add agent against doctors IV publication its said important know that use because There more antihistamines. in that also the in [indiscernible] histamine on paclitaxel a immunosuppressive we suggesting in response tumor. of will literature an TX the little using the for were is formulation, own which you

not of such add So steroid highlight all can at Oral assuming as mean part Cremophor this together both be for for will Abraxane clinical this and Paclitaxel, paclitaxel we antihistamine because interesting medications and medications. want to I you need with observation therefore, and the of that do look studies, in you just IV if this present P I that not confirm then P the to of observation. combination

Operator

the next from Leerink. Chang Jonathan comes question SVB of Our with line

John Barrett

This progress. Congrats Barrett on for Jonathan. is on John the

your SABCS help presentation, investor you expectations Regarding regarding set the upcoming update? can

Dr. Johnson Lau

Sure.

abstracts strategy directly on on the We suscept usual four management highlights. data and the the two have

want with to four regard abstracts the do details Rudolf, data, to you these Now on more for provide the abstracts?

Dr. Rudolf Kwan

Absolutely.

Paclitaxel versus The Oral with and title analysis San PD-X-XX first last And following and progression-free in data the data from patients, include the an on XXX Paclitaxel and presentation, survival, presentation further a these the FDA discussion the of represent in best analysis. update Antonio year data how it new of data treatment the present ago. the guidance the a survival the to MBC and cut overall poster basically IV on spotlight Encequidar embargo is

angiosarcoma additional very that. that's would patients results that cancer so follow And we embargo, very difficult-to-treat certainly, with and angiosarcoma. cutaneous more the who those coming on about PSXXXX, see poster data is of to group the certainly, I surgery presentation. treatment you So One And present The is The subgroup talk encouraging encourage is up a patient irradiation lower presentation, that Oral be PSXXXX on And Then present further rate will poster and we the neuropathy. again Paclitaxel neuropathy Encequidar Oral a the regarding in are focusing of and with we a that. XXX in And management data. premedication data side those Paclitaxel how is and presented GI data Encequidar, managed data. how study I positive about had present the the and angiosarcoma. with how will years we'll and breast of PSXXXX cannot manage later common population. and in effects, cutaneous prophylaxis has inference

those that think four attend are you I and symposium really data So the the virtual posters the I to encourage see yourself.

John Barrett

more. a provide chemotherapies one update other datas those just progress And your you see Can we programs? when for might on and oral

Dr. Rudolf Kwan

nutshell, can I that. In focusing submissions. on busy very have a Certainly, provide two we been

certainly, So and two with And those whole especially with interactive really the COVID-XX we whole down perspective. enrolling our the review and being approvals FDA slow any team, on FDA and do a the haven't don't parity the when But environment focus review, MTA the the really the from you interaction knitting that. with we very X down show focusing also got patients. constant -- on size is lost

along. Our even, can recently, cycle management did is but look be program. in all do those all that. down we the a certainly, busily other Paclitaxel, COVID-XX TCR-T are And when that some moving of But you we as only to developing teams include will are slow all continue approval the life IND see, programs enrollment the Oral the not at testament

in of that the as communicate decisions are we soon as will have sometime And on once we we communication XXXX. dates So thinking PDUFA two can. we

Operator

& comes next line Our question from of the Oppenheimer DeGeeter Company. Kevin with

Kevin DeGeeter

your Antonio. we up to just really how about benefit data. more the shown described? this With update It think thinking San Paclitaxel? you've on Or the update, overall cancer construed of the about can interesting we provide an for more but that should expect indication, smaller addressable steps for narrowly population enrolled update angiosarcoma on you being next the across How generally expansion angiosarcoma, Maybe regard us is Oral into And does to you're to angiosarcoma market just and as breast regulatory cohort? strategies the of should on following duration some a an fit update program?

Dr. Johnson Lau

Rudolf?

Dr. Rudolf Kwan

Yes. is think, data present really Sure. indication, interesting in I patients It's I a the bear in well received Designation do already. indication. will intend And U.S. the Designation breast. Orphan believe Drug FDA explore is subset on as Drug angiosarcoma there's as angiosarcoma some very Designation. we and it small well. do the the we we of is in what study have And seven we very based Orphan and progressing really intriguing of program, It's Orphan U.S. generating we approval from the have the an but to the be also the very, the mind, The the, Drug presenting, in

put that that enough presentation. patients. for don't I seven the the cannot hope is a focusing we data believe the on we'll really you So on interesting I that metastatic I poster, in remember be study the is one. cancer. And all priority later is the knitting down our more because breast in relevant gave an indication. But speak, the -- as we I color exactly,

Kevin DeGeeter

Yes.

Dr. Johnson Lau

here. Johnson Kevin,

the Mr. to going Before we generate his lot to provide potential, ourselves reverse sarcoma, Cook that I oncologists, They alike. position in inquiry you on opinion clinical to in the the tumors Tim ask how also our angiosarcoma are angiosarcoma interested the study among a are oncologists. oncologists and very with of market regard is

also represents seeing we a create already. the are to that oncologists very us good the in momentum this way, with clinical So opportunity for a

marketing has want you make launch, and Tim Now with the regard our to a to do to any comment? it whether strategy market contribution sort of

Timothy Cook

Number meaningful and twofold. angiosarcoma difficult Sure, to as really of disease The Johnson. overall effective we're of the happy a Oral responses. improves treat. Paclitaxel to, is Thank is This rapid importance drug. you. seeing it one, And really an perception

you so And to about of when very want your think make creating you're drug, a sure perception that you first. positive efficacy

setting And we And the is really that metastatic second the cancer Paclitaxel I rapid responses. certainly creating showing in think on disease Oral builds with so here, have breast that responses we're that's strong setting. perception difficult-to-treat and this a

would may in say just they're treated, focused very limited I patient while opportunity, mainly a that it academic where centers. major be they're Secondly, in

So diagnosed high. these once is to capture pretty ability patients the

so And the very this, for overall important drug. disease, may orphan it's and a again, while smaller the be it niche opportunity perception to

Operator

Our from & the next line Company. Jen question of Laidlaw comes from Instructions] Yale [Operator

Yale Jen

two here. got I've

you first is medication have between you for the well The as as XXXB one and API dynamics the that drugs. the fourth the as quarter, the Jeff, into COVID-XX look

of you changed? mostly Or major that see And quick I for COVID-XX you have see do then So that part a that? the be dynamic still a follow-up. being

Jeff Yordon

see rising and falling. Yale. X, in we significant an last The seen hospital COVID, Yes, saw week the patients or with a and now again. uptick decline We it we've

I will you will that on have we And that raising expectations be track. be in quarter fine So overall, fourth for least the year-end come as by confident revenue the will at feel that tells a that expected. will quarter think and the we pretty about we

Yale Jen

the The actually follow-up here marketing side. is for

that Oral Have able in potential also value the to lot a guys if guys And proposition. premarketing to maybe so, and you done any publish mentioned pharmacoeconomic of Paclitaxel? you on and be You activities activity future? studies would

Timothy Cook

of important looking would Paclitaxel. because we're the is on we hospital to showing study much will any the we something overall and We in with tell in. be on their hospital effective. That's that conferences. and will Oral the done cost those. versus done very outside home have pharmacoeconomic though, some studies cost looking haven't we We've example, get cost presenting Once yet planned IV more for treatment publish pharmacoeconomic own associated treatment at, pharmacoeconomic at interested have I we not market, done Paclitaxel patients also you, at-home the absolutely a approved. of certainly future is payers overall That are due at neuropathies treating data that But that

We be care-focused publishing will journals. also near the managed future in in

it oral planned. we have done of between significant difference while society. Oral looking cost and on neuropathy Paclitaxel have again, we IV So don't But anything to at-home and the yet, overall pharmacoeconomics at, is the infusion

Operator

final Lau our any this gentlemen, and Ladies question-and-answer the to you. Dr. I'll floor Thank turn concludes back for session. comments.

Dr. Johnson Lau

today. we Athenex call for us with have interest. we commercial will again, your late time. is a results thank company the approved. have our time you XXXX, in evolved an February This stage into drugs joining for proprietary you, Thank hopefully and exciting appreciate everyone, your we full-year time And biotech By for

Operator

conference. you. This concludes today's Thank

may at participation. disconnect lines time. your Thank You this for you your

Athenex (ATNXQ) 5 Nov 202020 Q3 Earnings call transcript